SG Americas Securities
AVDL

SG Americas Securities’s Avadel Pharmaceuticals AVDL Stock Holding History

SG Americas Securities’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,366
Closed -$1.08M – 3218
2025
Q4 		$1.08M Buy
+50,366
New +$978K ﹤0.01% 1941
2025
Q1 		– Sell
-46,767
Closed -$492K – 3479
2024
Q4 		$492K Buy
46,767
+34,281
+275% +$416K ﹤0.01% 1361
2024
Q3 		$164K Buy
+12,486
New +$190K ﹤0.01% 2649
2022
Q4 		– Sell
-10,021
Closed -$50K – 3057
2022
Q3 		$50K Buy
+10,021
New +$55.2K ﹤0.01% 2992
2017
Q1 		– Sell
-13,258
Closed -$138K – 3267
2016
Q4 		$138K Buy
+13,258
New +$146K ﹤0.01% 2635

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

SG Americas Securities's AVDL Position: Q1 2026 in Review

SG Americas Securities sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 50,366 shares — an estimated $1.08M sold.

SG Americas Securities first reported a position in AVDL in Q4 2016 and held it in 5 quarters. The position peaked at $1.08M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • SG Americas Securities reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SG Americas Securities sold 50,366 Avadel Pharmaceuticals shares in Q1 2026, an estimated $1.08M.
  • SG Americas Securities first reported a position in Avadel Pharmaceuticals in Q4 2016 and held it in 5 quarters.
  • SG Americas Securities's Avadel Pharmaceuticals position peaked at $1.08M in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.